Improved mammalian expression vectors and uses thereof

    公开(公告)号:NZ600979A

    公开(公告)日:2014-01-31

    申请号:NZ60097909

    申请日:2009-01-15

    Applicant: ABBOTT LAB

    Inventor: HSIEH CHUNG-MING

    Abstract: 600979 Disclosed is an expression vector comprising: (a) an OriP origin of replication derived from Epstein-Barr virus (EBV); (b) an SV40 origin of replication; (c) an insertion site for inserting a gene of interest; (d) a promoter operably linked to the insertion site, wherein the promoter is a cytomegalovirus (CMV) promoter; and, optionally, (e) a nucleic acid sequence encoding an antibody heavy or light chain constant region, operably linked to the insertion site, wherein the OriP origin of replication is bound by a trans-acting EBNA1 replication initiation factor that is not encoded by the expression vector, or the SV40 origin of replication is bound by a trans-acting SV40 T antigen that is not encoded by the expression vector.

    METHODS FOR TRANSFORMING YEAST
    73.
    发明专利

    公开(公告)号:NZ587766A

    公开(公告)日:2013-06-28

    申请号:NZ58776609

    申请日:2009-03-03

    Applicant: ABBOTT LAB

    Abstract: NZ 587766 Disclosed is a method of preparing a yeast library by electroporation of yeast cells, the method comprising the steps of: incubating the yeast cells in a solution comprising lithium acetate (LiAc) and dithiothreitol (DTT); providing a suspension comprising vector DNA, insert DNA, yeast cells, 0.1 to 10 M sorbitol, and 0.1 to 10 mM CaCl2 or MgCl2; and electroporating the suspension at 0.5kV/cm to greater than 12.5kV/cm with a capacitance of about 10 to about 50 mu ?F.

    METHODS FOR TRANSFORMING YEAST
    74.
    发明专利

    公开(公告)号:SG188846A1

    公开(公告)日:2013-04-30

    申请号:SG2013016084

    申请日:2009-03-03

    Applicant: ABBOTT LAB

    Abstract: Methods for Transforming Yeast AbstractThis invention is directed to the transformtion of yeast, and mutants thereof, by electroporation, which result in stably transformed yeast host cells that express recombinant products. This invention also is directed to transformed yeast cells and libraries.Figure I

    PROTEINAS DE UNION A PROSTAGLANDINA E2 Y USOS DE LAS MISMAS.

    公开(公告)号:MX2010014573A

    公开(公告)日:2011-09-16

    申请号:MX2010014573

    申请日:2010-12-21

    Applicant: ABBOTT LAB

    Abstract: La presente invención abarcar proteínas de unión de prostaglandina E2 (PGE2). La invención se refiere a anticuerpos que son de tipo silvestre, quiméricos, de CDR injertada y humanizados. Los anticuerpos preferidos tienen alta afinidad para prostaglandina E2 y neutralizan la actividad de prostaglandina E2 in vitro e in vivo. Un anticuerpo de la invención puede ser un anticuerpo de longitud completa, o una porción de unión a antígeno del mismo. También se proporcionan métodos para hacer y métodos para utilizar los anticuerpos de la invención. Los anticuerpos, o porciones de unión a antígeno, de la invención son útiles para detectar prostaglandina E2 y para inhibir la actividad de prostaglandina E2, por ejemplo, en un ser humano que sufre de un trastorno en donde la actividad de prostaglandina E2 es dañina.

    IL-1 BINDING PROTEINS
    78.
    发明专利

    公开(公告)号:SG172855A1

    公开(公告)日:2011-08-29

    申请号:SG2011049012

    申请日:2010-01-29

    Applicant: ABBOTT LAB

    Abstract: The present invention encompasses IL-1α binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Antibodies of the invention have high affinity for IL-1α and neutralize IL-1α activity. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting IL-1α and for inhibiting IL-1α activity, e.g., in a human subject suffering from a disorder in which IL-1α activity is detrimental.

Patent Agency Ranking